Novartis targets hepatitis remedies
Novartis AG said that it would buy a majority stake in Idenix Pharmaceuticals Inc., a closely held U.S. company, and jointly develop potential drugs for hepatitis C, hoping to break into a lucrative
Novartis AG said that it would buy a majority stake in Idenix Pharmaceuticals Inc., a closely held U.S. company, and jointly develop potential drugs for hepatitis C, hoping to break into a lucrative